全文获取类型
收费全文 | 1075篇 |
免费 | 70篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 51篇 |
妇产科学 | 19篇 |
基础医学 | 141篇 |
口腔科学 | 37篇 |
临床医学 | 70篇 |
内科学 | 242篇 |
皮肤病学 | 23篇 |
神经病学 | 36篇 |
特种医学 | 159篇 |
外国民族医学 | 1篇 |
外科学 | 80篇 |
综合类 | 53篇 |
预防医学 | 64篇 |
眼科学 | 6篇 |
药学 | 102篇 |
中国医学 | 4篇 |
肿瘤学 | 57篇 |
出版年
2022年 | 5篇 |
2021年 | 13篇 |
2020年 | 8篇 |
2019年 | 13篇 |
2018年 | 21篇 |
2017年 | 21篇 |
2016年 | 24篇 |
2015年 | 23篇 |
2014年 | 22篇 |
2013年 | 36篇 |
2012年 | 42篇 |
2011年 | 42篇 |
2010年 | 47篇 |
2009年 | 57篇 |
2008年 | 46篇 |
2007年 | 31篇 |
2006年 | 30篇 |
2005年 | 19篇 |
2004年 | 29篇 |
2003年 | 22篇 |
2002年 | 21篇 |
2001年 | 19篇 |
2000年 | 19篇 |
1999年 | 15篇 |
1998年 | 36篇 |
1997年 | 36篇 |
1996年 | 35篇 |
1995年 | 38篇 |
1994年 | 27篇 |
1993年 | 25篇 |
1992年 | 12篇 |
1991年 | 15篇 |
1990年 | 17篇 |
1989年 | 30篇 |
1988年 | 31篇 |
1987年 | 20篇 |
1986年 | 27篇 |
1985年 | 17篇 |
1984年 | 20篇 |
1983年 | 23篇 |
1982年 | 14篇 |
1981年 | 19篇 |
1980年 | 17篇 |
1979年 | 9篇 |
1978年 | 11篇 |
1976年 | 12篇 |
1975年 | 6篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1966年 | 3篇 |
排序方式: 共有1149条查询结果,搜索用时 15 毫秒
101.
102.
Cloning, functional activities and in vivo tissue distribution of rat NKR-P1+ TCR alpha beta + cells
Knudsen E; Seierstad T; Vaage JT; Naper C; Benestad HB; Rolstad B; Maghazachi AA 《International immunology》1997,9(7):1043-1051
We have successfully cloned nine NKR-P1+ TCR alpha beta + cells from PVG
rat spleens, utilizing murine macrophage inflammatory protein-1 alpha
(MIP-1 alpha) and IL-2. These clones are either double negative (DN,
CD4-CD8-), which included clones 3.31, 3.71, 4.19, 4.59 and 4.65, or single
positive (SP, CD4+CD8-), which included clones 1.64, 3.8, 3.76 and 3.78. No
CD8+ clone was recovered. All nine clones are restricted in terms of their
expression of the V beta antigens, since they express V beta 8.2 but not V
beta 8.5, V beta 10 or V beta 16. These clones are agranular and they fall
to generate NK or LAK activity upon incubation with IL-2, IL-12 or their
combination. On the basis of their production of intracellular cytokines
they can be divided into three categories: (I) SP clones (1.64, 3.8, 3.76
and 3.78) do not produce IL-2 or IL-4, but produce IFN-gamma and IL-12, and
they vary in their production of IL-1, RANTES or tumor necrosis factor
(TNF)-alpha; (II) DN clones 4.59 and 4.65 produce IL-1 alpha and IFN-gamma
only, and fall to produce other cytokines; and (III) DN clones 3.31, 3.71
and 4.19 produce IL-1 alpha, IL-1 beta, IL-2, IL-12, IFN-gamma, RANTES and
TNF-alpha. From all the clones examined only DN clones 3.31 and to a lesser
degree 4.19 produce IL-4. In vivo tissue localization of clones 3.8, 3.31
and 4.59 shows that these cells distribute into the liver and bone marrow
24 h post i.v. administration. Their accumulation in the liver and bone
marrow along with their ability to secrete various cytokines suggest that
these cells may influence the generation, differentiation or apoptosis of
immune or hematopoietic cells.
相似文献
103.
104.
105.
F Bambi ; LB Faulkner ; C Azzari ; AM Gelli ; A Tamburini ; V Tintori ; AA Lippi ; F Tucci ; G Bernini ; F Genovese 《Transfusion》1998,38(1):70-74
BACKGROUND: An increasing number of apheresis machines are becoming available for peripheral blood progenitor cell (PBPC) collection in children. STUDY DESIGN AND METHODS: At the Children's Hospital of Florence (Italy), three apheresis machines were evaluated: MCS 3P (Haemonetics) (10 procedures in 4 patients, aged 10–12 years, weight 23.5-64 kg), Spectra, (COBE) (8 procedures in 3 patients, aged 4–17 years, weight 19–59 kg), and AS104 (Fresenius) (24 procedures in 9 patients, aged 2–16 years, weight 13.6-60 kg). For PBPC quantitative analysis, CD34 cytofluorimetry was employed. Relevant variables analyzed included efficiency of CD34+ cell extraction and enrichment, mononuclear cell purity and red cell contamination of the apheresis components, and platelet count decreases after leukapheresis. RESULTS: No significant differences in CD34+ cell-extraction abilities were found. However, the AS104 provided consistently purer leukapheresis components in terms of mononuclear cell and CD34+ cell enrichment (441 +/− 59%, vs. 240 +/− 35% and 290 +/− 42% for MCS 3P and Spectra, respectively). Postapheresis platelet counts dropped the least with the AS104. The smallest patient who underwent apheresis with MCS 3P (the only machine working on discontinuous flow and hence with greater volume shifts) weighed 23.5 kg and tolerated the procedure well, with no signs of hemodynamic instability. No significant complications were observed. CONCLUSION: All machines seem to have comparable PBPC extraction efficiency, but the AS104 seems to give the component with the greatest PBPC enrichment. This feature might be relevant for further ex vivo cell processing (CD34+ cell selection, expansion, and so on). 相似文献
106.
Stimulation of eosinophil production in vitro by eosinophilopoietin and spleen-cell-derived eosinophil growth-stimulating factor 总被引:4,自引:0,他引:4
Eosinophilopoietin (EPP) was previously characterized by the ability to stimulate eosinophil production in vivo, but these studies could not ascertain whether EPP had a direct effect on the bone marrow or acted indirectly by causing release of eosinophilopoietic activity by other tissues. The present studies demonstrate that EPP stimulates eosinophil growth in liquid culture of mouse bone marrow in vitro. The timing of stimulation by EPP in vivo and in vitro were parallel, with maximal eosinophil growth after 48 hr. Moreover, EPP appears similar to, and possible identical with, the eosinophil growth-stimulating substance (EO-GSF) released by antigenic stimulation of immune nonadherent spleen cells. Both EPP and EO-GSF are of low molecular weight, both produce stimulation of eosinophil growth with identical kinetics, and both produced similar dose-response curves in the liquid culture system. 相似文献
107.
Dr. Jose Milei J. J. Ale Guy Garay Fernando Otero Alberto Zori Comba Humberto O. Gugliotta Ruben A. Storino 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1990,4(6):1519-1523
Summary Adriamycin (ADM) is an effective antineoplastic drug. However, the amount of ADM that can be administered must be limited because of the risk of developing a severe dose-dependent cardiomyopathy. 4Epi-adriamycin (4 ADM) is a new anthracycline analog with similar antineoplastic properties as ADM, but with perhaps less cardiac toxicity. To determine myocardial performance after a chronic treatment with 4ADM, we studied 17 patients (mean age 36.6 years) suffering from lymphomas by means of 24-hour ambulatory ECG, x-ray, M-mode echocardiogram, and rest-exercise gated radionuclide ventriculography (RNV), performed prior to and 2 months after the end of the treatment. Pretreatment and post-treatment shortening fractions, basal pretreatment and post-treatment ejection fractions, and postexercise pretreatment and post-treatment ejection fractions, were tested for correlation with individual 4ADM doses and pretreatment with ADM. No association was noted among them, showing the lack of correlation between doses and impairment of ventricular performance. 4ADM doses ranged from 400 to 1100,
748±174 mg/m2; allnoninvasive studies including RNV doses and RNV (Pearson's correlation coefficient, p=ns). No deterioration of ventricular performance could be demonstrated. Conversely, the basal pretreatment ejection fraction changed from 56.17±7.6% to 61.52±8.3% in posttreatment (p<0.0001). Surprisingly, the postexercise pretreatment ejection fraction also increased from 55.47±7.7% to 63.35±10% in post-treatment (p<0.03). The shortening fraction changed from 35.47±4.8% to 36.47±4.2% after 4ADM treatment (ns). No impairment of cardiac function could be shown in patients previously treated with ADM or radiotherapy. On the basis of these data, treatment with 4ADM did not impair but improved cardiac function 相似文献
108.
Can pH recordings suggest defective esophageal peristalsis in patients with gastroesophageal reflux?
P Parrilla L F Martinez de Haro A Ortiz G Morales J Cifuentes D Videla V Garay 《Scandinavian journal of gastroenterology》1992,27(11):929-932
The data provided by 24-h pH monitoring in 40 patients with gastroesophageal reflux, divided in three groups in accordance with esophageal motor pattern, were compared. Patients with hypomotility had significantly greater reflux rates than those with normal motility or hypermotility, if we consider both total time with pH < 4 and time with pH < 4 corresponding to episodes of > 5 min duration. We conclude that when 24-h pH monitoring shows very high reflux rates, basically corresponding to episodes lasting > 5 min, we should suspect the presence of defective esophageal peristalsis, which must be confirmed with a manometric study. 相似文献
109.
110.
Pancreatic undifferentiated carcinoma with osteoclast‐like giant cells is genetically similar to,but clinically distinct from,conventional ductal adenocarcinoma 下载免费PDF全文
Claudio Luchini Antonio Pea Gemma Lionheart Andrea Mafficini Alessia Nottegar Nicola Veronese Peter Chianchiano Lodewijk AA Brosens Michaël Noë G Johan A Offerhaus Raluca Yonescu Yi Ning Giuseppe Malleo Giulio Riva Paola Piccoli Ivana Cataldo Paola Capelli Giuseppe Zamboni Aldo Scarpa Laura D Wood 《The Journal of pathology》2017,243(2):148-154
Undifferentiated carcinoma of the pancreas with osteoclast‐like giant cells (UCOGC) is currently considered a morphologically and clinically distinct variant of pancreatic ductal adenocarcinoma (PDAC). In this study, we report clinical and pathological features of a series of 22 UCOGCs, including the whole exome sequencing of eight UCOGCs. We observed that 60% of the UCOGCs contained a well‐defined epithelial component and that patients with pure UCOGC had a significantly better prognosis than did those with an UCOGC with an associated epithelial neoplasm. The genetic alterations in UCOGC are strikingly similar to those known to drive conventional PDAC, including activating mutations in the oncogene KRAS and inactivating mutations in the tumor suppressor genes CDKN2A, TP53, and SMAD4. These results further support the classification of UCOGC as a PDAC variant and suggest that somatic mutations are not the determinants of the unique phenotype of UCOGC. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献